ImmunoPrecise Antibodies names Yasmina Noubia Abdiche as chief scientific officer

ImmunoPrecise Antibodies Ltd (OTCMKTS:IPATF) (CVE:IPA), the antibody discovery specialist, has appointed Dr Yasmina Noubia Abdiche as the group's chief scientific officer (CSO) with effect from April this year. "We are excited to have Dr. Abdiche join the ImmunoPrecise team," Dr Jennifer Bath, ImmunoPrecise's president and CEO said in a statement. READ: ImmunoPrecise Antibodies and its AI collaborator team up on research program to help fight coronavirus "She has a distinguished background in therapeutic antibody discovery and a strong track record of advancing drugs to the clinic. With over 15 years of industry experience Dr Abdiche is a highly respected, strategic and skilled thought leader with solid scientific and business acumen," Bath added. Among other things, Abdiche, an Oxford graduate, will lead the company's global research and development teams. Most recently she was CSO at Utah-based biotech Carterra, where she helped transition its analytical antibody screening platform from concept through prototype to global commercialization. Abdiche previously was a Research Fellow on the leadership team at Rinat-Pfizer where she led a team of scientists providing core support for biomolecular interaction analysis and played an active role on the governing committee for Pfizer's Postdoctoral program, added the company. She is co-inventor of several therapeutic antibodies that entered clinical trials including a current, market-approved drug Ajovy. Earlier this week, ImmunoPrecise Antibodies revealed that it, along with its artificial intelligence collaborator, were teaming up to join the global fight against coronavirus. The company announced Monday that its partner EVQLV had submitted its first panel of DNA sequences that may offer potential therapeutic antibodies against the new coronavirus, SARS CoV-2 or COVID-19. The DNA sequences were generated by EVQLV using computational antibody design, combining mathematics, statistics and computer science to pinpoint high-affinity antibodies. Contact the author at giles@proactiveinvestors.com